Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pediatric acceptability study of two oral hydrocortisone magistral formulations
2024-519149-31-00Phase 4Authorised
- Sponsor
- Vall d'Hebron Research Institute
- Start
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of hydrocortisone in congenital adrenal hyperplasia (CAH), Addison's disease, Adrenocorticotropic hormone and 2 more (2 arms), sponsored by Vall d'Hebron Research Institute. Primary endpoint: Sensory acceptability of the formulation. Planned start Oct 2026; status: authorised.
02
Drugs
hydrocortisone
03
Conditions
congenital adrenal hyperplasia (CAH)Addison's diseaseAdrenocorticotropic hormonetertiary adrenal insufficiency (TAI)panhypopituitarism
Beyond the preview
Go deeper on 2024-519149-31-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519149-31-00.